Computer-aided design and synthesis of tetra-aryl-substituted alkenes and their bioevaluation as a selective modulator of estrogen-related receptor γ

Molecular Diversity

Volumn 15, Issue 1, 2011, Pages 69-81

  Koh, Minseob ^a   Park, Seung Bum ^a  

^a Seoul National University   (South Korea)

Author keywords

Antagonist; Computational docking; Estrogen receptor (ER ); Estrogen related receptor (ERR ); Inverse agonist; Tamoxifen analogs

Indexed keywords

4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 BIS(3 FLUORO PHENYL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 BIS(4 FLUORO PHENYL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(1H PYRAZOL 4 YL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(FURAN 3 YL)VINYL PHENOL; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(FURAN 3 YL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(PYRIDIN 3 YL)VINYL PHENOL; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(PYRIDIN 3 YL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(PYRIDIN 4 YL)VINYL PHENOL; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(PYRIDIN 4 YL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(PYRIMIDIN 5 YL)VINYL PHENOL; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(THIOPHEN 2 YL)VINYL PHENYL PIVALATE; 4 [1 [4 (2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2,2 DI(THIOPHEN 3 YL)VINYL PHENYL PIVALATE; 4 [2,2 DIBROMO 1] (4 HYDROXYPHENYL)VINYL PHENYL PIVALATE; 4 [2,2 DIBROMO [1 4 (2 (DIMETHYLAMINO)ETHOXY)PHENYL] VINYL] PHENYL PIVALATE; 4,4' (2,2 DIBROMOETHENE 1,1 DIYL)BIS(4,1PHENYLENE) BIS(2,2 DIMETHYLPROPANOATE); 4,4' CARBONYLBIS(4,1 PHENYLENE)BIS(2,2 DIMETHYLPROPANOATE); AFIMOXIFENE; ALKENE; ANTIESTROGEN; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR GAMMA; STEROID RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; COMPUTER AIDED DESIGN; CONFERENCE PAPER; DRUG DESIGN; DRUG SELECTIVITY; HYDROGEN BOND; ISOMERIZATION; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; REPORTER GENE; SYNTHESIS; TRANSCRIPTION REGULATION;

ALKENES; AMINO ACID MOTIFS; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG INVERSE AGONISM; ESTROGEN RECEPTOR ALPHA; HEK293 CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN;

EID: 79953318868     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11030-010-9224-y     Document Type: Conference Paper

References (30)

1. Eudy JD, Yao S, Weston MD, Ma-Edmonds M, Talmadge CB, Cheng JJ, Kimberling WJ, Sumegi J (1998) Isolation of a gene encoding a novelmember of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. Genomics 50:382-384 (Pubitemid 28328760)
2. Hong H, Yang L, Stallcup MR (1999) Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptorERR3. J Biol Chem 274: 22618-22626. doi:10.1074/jbc.274.32.22618
3. Heard DJ, Norby PL, Holloway J, Vissing H (2000) Human ERR γ , a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol 14:382-392. doi:10.1210/me.14.3.382
4. Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M, Jonker JW, Giles W, Naviaux RK, Giguere V (2007) ERR γ directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6:13-24. doi:10.1016/j.cmet.2007.06.007 (Pubitemid 46995781)
5. Ariazi EA, Clark GM, Mertz JE (2002) Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62:6510-6518 (Pubitemid 35364116)
6. Cheung CP, Yu S,Wong KB, Chan LW, Lai FM,Wang X, Suetsugi M, Chen S, Chan FL (2005) Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 90:1830-1844. doi:10.1210/jc.2004-1421 (Pubitemid 40464058)
7. Dufour CR,Wilson BJ, Huss JM,Kelly DP,AlaynickWA,Downes M, Evans RM, Blanchette M, Giguère V (2007) Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERR α and γ. Cell Metab 5:345-356. doi:10.1016/j.cmet.2007.03.007 (Pubitemid 46667756)
8. Huss JM, Kopp RP, Kelly DP (2002) Peroxisome proliferator- activated receptor coactivator-1alpha (PGC-1α) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor- α and - γ . Identification of novel leucinerich interaction motif within PGC-1 alpha. J Biol Chem 277:40265-40274. doi:10.1074/jbc.M206324200 (Pubitemid 35215598)
9. Yu S, Wang X, Ng C-F, Chen S, Chan FL (2007) ERR γ suppresses cell proliferation and tumor growth of androgensensitive and androgen-insensitive prostate cancer cells and its implications as a therapeutic target for prostate cancer. Cancer Res 67:4904-4914. doi:10.1158/0008-5472.CAN-06-3855 (Pubitemid 46915313)
10. Horard B, Vanacker J-M (2003) Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endo 31:349-357. doi:10.1677/jme.0.0310349 (Pubitemid 38054510)
11. Giguère V (2002) To ERR in the estrogen pathway. Trend Endocrinol Metab 13:220-225. doi:10.1016/S1043-2760(02)00592-1
12. Chao EYH, Collins JL, Gaillard S, Miller AB, Wang L, Orband- Miller LA, Nolte RT, McDonnell DP, Willson TM, Zuercher WJ (2006) Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRγ. BioorgMed Chem Lett 16:821-824. doi:10.1016/j.bmcl.2005.11.030 (Pubitemid 43059830)
13. Kim Y, Koh M, Kim D-K, Choi H-S, Park SB (2009) Efficient discovery of selective small molecule agonists of estrogen-related receptor γ using combinatorial approach. J Comb Chem 11: 928-937. doi:10.1021/cc900081j
14. Montfort RLM, Workman P (2009) Structure-based design of molecular cancer therapeutics. Trend Biotech 27:315-328. doi:10.1016/j.tibtech.2009.02.003
15. Dailey MM, Hait C, Holt PA, Maguire JM, Meier JB, Miller MC, Petraccone L, Trent JO (2009) Structure-based drug design: From nucleic acid to membrane protein targets. Exp Mol Pathol 86: 141-150. doi:10.1016/j.yexmp.2009.01.011
16. Barker JJ (2006) Antibacterial drug discovery and structure-based design. Drug Discov Today 11:391-404. doi:10.1016/j.drudis.2006.03.001
17. Yu DD, FormanBM (2003) Simple and efficient production of (Z)- 4-Hydroxytamoxifen, a potent estrogen receptor modulator. J Org Chem 68:9489-9491. doi:10.1021/jo035164n
18. Accelrys Software Inc. 10188 Telesis Court, Suite 100 San Diego, CA 92121, USA. http://accelrys.com
19. Sambrook J, Russel DW (2001) Molecular cloning: a laboratory manual, vol 3, 3rd edn. CSHL Press, New York, pp 16.21-16.26
20. Greschik H, Flaig R, Renaud J-P, Moras D (2004) Structural basis for the deactivation of the estrogen-related receptor γ by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 279:33639-33646. doi:10.1074/jbc.M402195200 (Pubitemid 39063013)
21. Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband-Miller LA, McKee DD, Willson TM, Nolte RT (2006) X-ray crystal structures of the estrogen-related receptor- γ ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J Biol Chem 281:37773-37781. doi:10.1074/jbc.M608410200 (Pubitemid 46042080)
22. Jordan VC (1995) TAMOXIFEN: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35:195-211. doi:10.1146/annurev.pa.35.040195.001211
23. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119 (Pubitemid 14178070)
24. Dugave C, Demange L (2003) Cis-Trans isomerization of organic molecules and biomolecules: implications and applications. Chem Rev 103:2475-2532. doi:10.1021/cr0104375
25. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EJ (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy,4′-hydroxy and N-desmethyl metabolite and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874. doi:10.1124/dmd.30.8.869 (Pubitemid 34815415)
26. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007) Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35: 1942-1948. doi:10.1124/dmd.107.016279 (Pubitemid 47481590)
27. Robertson DW, Katzenellenbogen JA, Logn DJ, Rorke EA, Katzenellenbogen BS (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Ster Biochem 16:1-13 (Pubitemid 12158097)
28. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem 4:187-217. doi:10.1002/jcc.540040211
29. Corey EJ, Fuchs PL (1972) A synthetic method for formyl → ethynyl conversion (RCHO→RC≡CH or RC≡CR′). Tetrahedron Lett 13:3769-3772. doi:10.1016/S0040-4039(01)94157-7
30. Bauer A, Miller MW, Vice SF, McCombie SW (2001) Suzuki arylation of 1,1-dibromo-1-alkenes: synthesis of tetra-substituted alkenes. Synlett 2:254-256. doi:10.1055/s-2001-10776 (Pubitemid 32154243)